50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Sell every Stock except ONE (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Sell every Stock except ONE (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Sell every Stock except ONE (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Sell every Stock except ONE (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Sell every Stock except ONE (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Sell every Stock except ONE (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Sell every Stock except ONE (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Sell every Stock except ONE (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Sell every Stock except ONE (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Sell every Stock except ONE (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Sell every Stock except ONE (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Sell every Stock except ONE (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
NYSE:DNA

Ginkgo Bioworks - DNA Short Interest Ratio & Short Volume

$2.80
0.00 (0.00%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.74
$2.90
50-Day Range
$2.41
$3.74
52-Week Range
$2.09
$15.86
Volume
19.05 million shs
Average Volume
21.38 million shs
Market Capitalization
$5.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.81

Ginkgo Bioworks Short Interest Data

Current Short Volume
179,060,000 shares
Previous Short Volume
144,250,000 shares
Change Vs. Previous Month
+24.13%
Dollar Volume Sold Short
$481.67 million
Short Interest Ratio / Days to Cover
7.0
Last Record Date
August 31, 2022
Outstanding Shares
1,784,833,000 shares
Float Size
783,990,000 shares
Short Percent of Float
22.84%
Today's Trading Volume
19,048,361 shares
Average Trading Volume
21,382,123 shares
Today's Volume Vs. Average
-10.91%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Ginkgo Bioworks ?

Sign up to receive the latest short interest report for Ginkgo Bioworks and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

DNA Short Interest Over Time

DNA Days to Cover Over Time

DNA Percentage of Float Shorted Over Time



Ginkgo Bioworks (NYSE:DNA) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/31/2022179,060,000 shares $481.67 million +24.1%22.8%7 $2.69
8/15/2022144,250,000 shares $503.43 million -4.0%18.4%5.5 $3.49
7/31/2022150,270,000 shares $429.77 million +3.9%19.8%6.5 $2.86
7/15/2022144,640,000 shares $433.92 million +7.5%19.1%6.2 $3.00
6/30/2022134,540,000 shares $320.21 million +22.4%17.8%5.7 $2.38
6/15/2022109,920,000 shares $284.69 million -14.7%14.6%4.3 $2.59
5/31/2022128,780,000 shares $396.64 million +19.1%17.1%5.6 $3.08
5/15/2022108,160,000 shares $287.71 million +16.9%14.4%5.2 $2.66
4/30/202292,500,000 shares $268.25 million +13.8%11.8%5 $2.90
4/15/202281,300,000 shares $312.19 million +9.7%10.3%4.6 $3.84
3/31/202274,120,000 shares $298.70 million -16.4%9.4%4.4 $4.03
3/15/202288,670,000 shares $258.03 million +2.9%9.3%7.1 $2.91
2/28/202286,190,000 shares $387.86 million +1.5%9.4%7.3 $4.50
2/15/202284,950,000 shares $471.47 million -9.2%9.2%7.5 $5.55
1/31/202293,570,000 shares $559.55 million +30.3%10.2%8.9 $5.98
1/15/202271,830,000 shares $415.90 million +30.0%8.6%8.2 $5.79
12/31/202155,270,000 shares $459.29 million No Change6.4%7 $8.31













DNA Short Interest - Frequently Asked Questions

What is Ginkgo Bioworks' current short interest?

Short interest is the volume of Ginkgo Bioworks shares that have been sold short but have not yet been covered or closed out. As of August 31st, traders have sold 179,060,000 shares of DNA short. 22.84% of Ginkgo Bioworks' shares are currently sold short. Learn More on Ginkgo Bioworks' current short interest.

What is a good short interest ratio for Ginkgo Bioworks?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNA shares currently have a short interest ratio of 7.0. Learn More on Ginkgo Bioworks's short interest ratio.

Which institutional investors are shorting Ginkgo Bioworks?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ginkgo Bioworks: Goldman Sachs Group Inc., Jane Street Group LLC, Pura Vida Investments LLC, Citadel Advisors LLC, Concourse Financial Group Securities Inc., Group One Trading L.P., Bank of Montreal Can, Cowen AND Company LLC, National Bank of Canada FI, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Ginkgo Bioworks?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 22.84% of Ginkgo Bioworks' floating shares are currently sold short.

Is Ginkgo Bioworks' short interest increasing or decreasing?

Ginkgo Bioworks saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 179,060,000 shares, an increase of 24.1% from the previous total of 144,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Ginkgo Bioworks' float size?

Ginkgo Bioworks currently has issued a total of 1,784,833,000 shares. Some of Ginkgo Bioworks' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ginkgo Bioworks currently has a public float of 783,990,000 shares.

How does Ginkgo Bioworks' short interest compare to its competitors?

22.84% of Ginkgo Bioworks' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Ginkgo Bioworks: CRISPR Therapeutics AG (15.19%), Exelixis, Inc. (3.03%), Halozyme Therapeutics, Inc. (7.84%), Beam Therapeutics Inc. (22.09%), Abcam plc (0.40%), Denali Therapeutics Inc. (6.52%), Vir Biotechnology, Inc. (6.27%), BioCryst Pharmaceuticals, Inc. (15.01%), Relay Therapeutics, Inc. (21.23%), and Fate Therapeutics, Inc. (22.31%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($4.91 billion), Charter Communications, Inc. ($3.53 billion), Suncor Energy Inc. ($2.26 billion), T. Rowe Price Group, Inc. ($2.01 billion), Chesapeake Energy Co. ($1.92 billion), Lucid Group, Inc. ($1.84 billion), Plug Power Inc. ($1.81 billion), Williams-Sonoma, Inc. ($1.66 billion), Coinbase Global, Inc. ($1.64 billion), and Lumen Technologies, Inc. ($1.50 billion). View all of the most shorted stocks.

What does it mean to sell short Ginkgo Bioworks stock?

Short selling DNA is an investing strategy that aims to generate trading profit from Ginkgo Bioworks as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Ginkgo Bioworks?

A short squeeze for Ginkgo Bioworks occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNA, which in turn drives the price of the stock up even further.

How often is Ginkgo Bioworks' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNA, twice per month. The most recent reporting period available is August, 31 2022.



This page (NYSE:DNA) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.